Navigation Links
New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
Date:5/18/2008

a from Two

Multicenter, Randomized, Placebo-

controlled Trials

S1272 Lubiprostone is Effective and Well Poster; Sunday, May

Tolerated Through 48 Weeks of 18, 2008 from 8am-

Treatment in Adults with Irritable 5pm PDT; Poster

Bowel Syndrome and Constipation presentation from

12pm-2pm PDT

T1036 Health-Related Quality of Life in Poster; Tuesday,

Adults with Irritable Bowel Syndrome May 20, 2008 from

with Constipation: Results of a 8am-5pm PDT; Poster

Combined Analysis of Two Phase 3 presentation from

Studies with Lubiprostone 12pm-2pm PDT

M1706 Discontinuation of Lubiprostone Poster; Monday, May

Treatment for Irritable Bowel Syndrome 19, 2008 from 8am-

with Constipation is Not Associated 5pm PDT; Poster

with Symptom Increase or Recurrence: presentation from

Results from a randomized withdrawal 12pm-2pm PDT

study

Abstract Presentation

Number Abstract Title Type/Date/Time

Outcomes Data

T1029 Development of an Instrument to Assess Poster; Tuesday,

Treatment Satisfaction in Patients May 20, 2008 from

with Chronic Constipation 8am-5pm PDT; Poster

presentation from

12pm-2pm PDT

T1030 Similarities between Constipation with Poster; Tuesday,

and without Irritable Bowel Syndrome May 20, 2008 from

in a California Medicaid (Medi-Cal) 8am-5pm PDT; Poster

<
'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.; SucampoPharmaceuticals,
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
3. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
5. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
6. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
7. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
9. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
10. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...Data Published in ,The Lancet, and Presented at ES...- Results from a new international,study, the GISS...d dose of,omega-3 acid ethyl esters reduced all ca...scular reasons in patients with chronic heart,fail...nline version of ,The,Lancet, and were presented a...
(Date:9/4/2008)... Updated Survival Data for Ipilimumab to be Pre...tCall/ -- Medarex, Inc.,(Nasdaq: MEDX ) announced...,an investigational anti-CTLA-4 antibody, in mela...ons at the 33rd Congress of the European Society,f...-16, 2008 in Stockholm.,Many of the following abst...
(Date:9/3/2008)...ays: Wrong Question Asked. Wrong Children Studied....PRNewswire-USNewswire/ -- A Centers for Disease,Co...aims there is no link,between the MMR vaccine and ... this study does nothing to dispel the growing pub...aises several questions concerning design,and meth...
(Date:9/3/2008)...SELS, Belgium and GENEVA, Sept. 3 /- ...lestone in CHO based monoclonal antibody,productio...over 31 grams,per liter. This record level was acc...logies: (1) a high-performance stable Selexis CHO,... leading scientists at,Selexis SA using their prop...
Breaking Medicine Technology:New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3CDC Misses Target With Flawed MMR/Autism Study 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3How fast youll age is written in the bones TAU research finds 16411 1How fast youll age is written in the bones TAU research finds 16411 2Boston College biologists build a better mouse model for cancer research 16409 1Boston College biologists build a better mouse model for cancer research 16409 2UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 1UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 2UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 3UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam 16407 4An Eye Opening Look at Insomnia 16405 1An Eye Opening Look at Insomnia 16405 2
... 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc....nical trial of GVAX immunotherapy,for pancreatic c...ney Kimmel Cancer Center. The trial enrolled 60 pa...d GVAX after surgical,resection of their tumor and...n overall survival for these patients was previous...
...000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, 20...d today at the American Society of,Clinical Oncolo...e,clinical activity of cilengitide in patients wit...rly aggressive form of brain tumor.,Cilengitide is...he,tumor and its vasculature. , Fifty-two patients...
Other Medicine Technology:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...es that not only fight cocaine and methamphetamine...ms. The study was conducted by a team of researc...at Baylor College of Medicine (BCM). As part of t...xamined the effect of the vaccines on subjects adm...
...le of detecting and measuring all known forms of h...r physicians in managing patient therapy. Abbott ...nced today that Abbott has received CE marking for...eaction) test for monitoring hepatitis B (HBV) vir...
...ial Programme for Research and Training in Tropica...trengthening and expanding research to prevent and...rategy builds on the programmes 30-year record of ...egies and enhancing research capacity in countries...
...Advisory Board for its transplantation programs. I...on of its United States (U.S.) clinical developme... and Larry Chodoff LifeCycle Pharma A/S OMX:LCP) t...Scientific Advisory Board (SAB) of experts in the ...
Other Medicine News:Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 2Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 3Health News:LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation 2
It provides cranial support in either prone or supine positions for premature infants and young children.
It provides cranial support in either supine or semi-sitting procedures.
The modular Doro headrest system is designed for both invasive and non-invasive applications in head and neck surgery. It can be adapted to all standard operating tables. It offers the decisive advan
Bunnel hand drill with Jacobs chuck, chuck size 4 mm.
Medicine Products: